Swedish Orphan Biovitrum AB

LTS:0MTD (Sweden)  
kr 264.40 (+2.01%) Feb 20
29.70
P/B:
2.59
Market Cap:
kr 89.39B ($ 8.62B)
Enterprise V:
kr 109.78B ($ 10.61B)
Volume:
93.32K
Avg Vol (2M):
115.17K
Also Trade In:
Volume:
93.32K
Avg Vol (2M):
115.17K

Business Description

Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Name Current Vs Industry Vs History
Cash-To-Debt 0.03
Equity-to-Asset 0.46
Debt-to-Equity 0.61
Debt-to-EBITDA 2.94
Interest Coverage 5.01
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.05
Distress
Grey
Safe
Beneish M-Score -2.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 62.14
9-Day RSI 49.32
14-Day RSI 47.22
6-1 Month Momentum % 42.68
12-1 Month Momentum % 22.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.81
Quick Ratio 0.52
Cash Ratio 0.05
Days Inventory 271.9
Days Sales Outstanding 73.32
Days Payable 62.78

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.2
Shareholder Yield % -14.31

Financials (Next Earnings Date:2024-04-26 Est.)

LTS:0MTD's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Swedish Orphan Biovitrum AB Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 21,269
EPS (TTM) (kr) 8.861
Beta 0.38
Volatility % 20.68
14-Day RSI 47.22
14-Day ATR (kr) 7.963178
20-Day SMA (kr) 271.055
12-1 Month Momentum % 22.87
52-Week Range (kr) 197.9 - 301.8
Shares Outstanding (Mil) 339.63

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Swedish Orphan Biovitrum AB Filings

Filing Date Document Date Form
No Filing Data

Swedish Orphan Biovitrum AB Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Swedish Orphan Biovitrum AB Frequently Asked Questions

What is Swedish Orphan Biovitrum AB(LTS:0MTD)'s stock price today?
The current price of LTS:0MTD is kr264.40. The 52 week high of LTS:0MTD is kr301.80 and 52 week low is kr197.90.
When is next earnings date of Swedish Orphan Biovitrum AB(LTS:0MTD)?
The next earnings date of Swedish Orphan Biovitrum AB(LTS:0MTD) is 2024-04-26 Est..
Does Swedish Orphan Biovitrum AB(LTS:0MTD) pay dividends? If so, how much?
Swedish Orphan Biovitrum AB(LTS:0MTD) does not pay dividend.

Press Release

Subject Date
No Press Release